Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Baishoukangdi Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner, PAK, MICHAEL D, who is the busiest examiner with 1 pending application. The prosecution is occurring within 1 distinct art unit, suggesting a specialized technical focus for the company's current filings.
The company's current patent activity is centralized, with 1 pending office action being the only matter requiring attention. Because PAK, MICHAEL D is the 1 distinct examiner involved, the prosecution strategy is dependent on the feedback from this single official. The focus on 1 distinct art unit suggests that the underlying technology is specialized within the Biotechnology & Pharmaceuticals field.
Practitioners should monitor the 1 pending office action closely, as its outcome will determine the success of the company's current filings. With 1 pending application assigned to PAK, MICHAEL D, the company can tailor its response to the specific preferences of this examiner. This 1 to 1 ratio of pending actions to examiners simplifies the management of the active portfolio at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641363 | METHOD FOR IDENTIFYING SUBSTANCE CAPABLE OF AFFECTING AGING | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641363 | METHOD FOR IDENTIFYING SUBSTANCE CAPABLE OF AFFECTING AGING | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17641363 | METHOD FOR IDENTIFYING SUBSTANCE CAPABLE OF AFFECTING AGING | PAK, MICHAEL D | 1674 | §102§112 | Final Rejection | — | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Baishoukangdi Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Pak has the most, with 1 of Zhejiang Baishoukangdi Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
